financetom
Business
financetom
/
Business
/
LTI Q3 net jumps 37% on higher revenues, margins
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
LTI Q3 net jumps 37% on higher revenues, margins
Jan 20, 2021 7:10 AM

Larsen & Toubro Infotech on Tuesday reported a 37.85 percent jump in net profit to Rs 519.3 crore for the December quarter, mainly driven by a surge in revenue and margin expansion. The IT arm of engineering major L&T had posted a net profit of Rs 376.7 crore in the year-ago period.

It reported a 12 percent increase in revenues to Rs 3,152.8 crore for the quarter as against Rs 2,811 crore a year ago. Compared to the preceding September quarter, the revenues were up nearly 6 percent.

Its chief executive and managing director Sanjay Jalona said the company's revenues have exceeded the levels attained in FY20 and exuded confidence of closing FY21 with revenue growth in high single digits.

The net income margin expanded to 16.5 percent as against 13.4 percent in the year-ago period and 15.2 percent in the preceding September quarter.

Jalona said a higher utilisation of over 84 percent, greater volume of work done onshore in India and faster revenue growth helped in the margin expansion.

The company is targeting to maintain the net income margin number between 14-15 percent and will be investing accordingly into the business because it wants to be seen as a growth company, Jalona said. Jalona said he is happy with the deal pipeline and the conversations with clients are centred around digital transformation and workforce modernisation contracts.

Refusing to comment on whether the worst is behind for the IT industry, which has been posting handsome performance numbers, Jalona said he is very optimistic about the vaccination.

The total headcount of the company increased to nearly 34,000 at the end of December from 31,419 in the year-ago period and 32,455 in the September quarter. Attrition also came down to 12.4 percent from 17.7 percent in the year-ago period.

The company scrip on Tuesday rose 1.93 percent to close at Rs 4,093.10 apiece on the BSE.

First Published:Jan 20, 2021 4:10 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Calidi Biotherapeutics (CLDI) Shares Are Trading Lower
Why Calidi Biotherapeutics (CLDI) Shares Are Trading Lower
Jul 8, 2024
Calidi Biotherapeutics Inc ( CLDI ) shares are trading lower by 14.3% to $0.17 during Monday’s session after the company announced a 1-for-10 reverse stock split, effective at 12:01 a.m. Eastern Time on July 15. The company’s common stock will begin trading on a split-adjusted basis on the NYSE American market under the symbol “CLDI”. The reverse stock split was...
FAA orders inspections of 2,600 Boeing 737 airplanes over oxygen mask issue
FAA orders inspections of 2,600 Boeing 737 airplanes over oxygen mask issue
Jul 8, 2024
WASHINGTON (Reuters) - The Federal Aviation Administration said Monday it is requiring inspections of 2,600 Boeing 737 airplanes because passenger oxygen masks could fail during an emergency. The FAA said it was requiring the inspections of 737 MAX and NG airplanes after multiple reports of passenger service unit oxygen generators shifting out of position, an issue that could result in...
Why XPeng Shares Are Moving Lower Monday
Why XPeng Shares Are Moving Lower Monday
Jul 8, 2024
XPeng ( XPEV ) stock is trading lower on Monday after China’s car sales dropped in June. The Details: China’s car sales decreased by 6.9% in June compared to last year, according to Reuters. Data from the China Passenger Car Association shows that June is the third consecutive month where Chinese car sales have declined. In April car sales fell...
Defence Therapeutics Secures NOL From Health Canada For Phase I Trial of AccuTOX
Defence Therapeutics Secures NOL From Health Canada For Phase I Trial of AccuTOX
Jul 8, 2024
12:08 PM EDT, 07/08/2024 (MT Newswires) -- Defence Therapeutics ( DTCFF ) , a Canadian biopharmaceutical company, on Monday said it secured a No Objection Letter (NOL) from Health Canada for its clinical trial of its AccuTOX cancer therapy The trial allows a Phase I trial of Intratumoral Administration of ACCUM-002TM as a Monotherapy and in Combination with Opdualag in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved